Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Moves Methylation-Based Prostate Cancer Prognostic to Affy Platform

NEW YORK (GenomeWeb News) —  Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.
The company said a concordance study showed a 98-percent agreement between the two platforms.  
Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.  
Epigenomics added that the demonstrating concordance should make regulatory clearance easier. The company also will file an Investigational Device Exemption in the first quarter of 2007.
The prostate test uses DNA methylation patterns to identify which patients who had undergone prostatectomies are at risk of recurrence, which happens in about one in seven cases.

The complete version of this article appears in this week's issue of BioArray News, a GenomeWeb News sister publication.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.